Suppr超能文献

非酒精性脂肪性肝炎与肝细胞癌风险。

Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.

机构信息

NAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.

Institute of Hepatology, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China.

出版信息

Chin Med J (Engl). 2021 Dec 1;134(24):2911-2921. doi: 10.1097/CM9.0000000000001888.

Abstract

The emergence of non-alcoholic fatty liver disease (NAFLD) as the leading chronic liver disease worldwide raises some concerns. In particular, NAFLD is closely tied to sedentary lifestyle habits and associated with other metabolic diseases, such as obesity and diabetes. At the end of the disease spectrum, non-alcoholic steatohepatitis (NASH) may progress to cirrhosis and hepatocellular carcinoma (HCC), representing a serious health problem to modern society. Recently, an increasing number of HCC cases originating from this progressive disease spectrum have been identified, with different levels of severity and complications. Updating the current guidelines by placing a bigger focus on this emerging cause and highlighting some of its unique features is necessary. Since, the drivers of the disease are complex and multifactorial, in order to improve future outcomes, having a better understanding of NASH progression into HCC may be helpful. The risks that can promote disease progression and currently available management strategies employed to monitor and treat NASH-related HCC make up the bulk of this review.

摘要

非酒精性脂肪性肝病 (NAFLD) 的出现成为全球主要的慢性肝病,引起了一些关注。特别是,NAFLD 与久坐的生活习惯密切相关,并与其他代谢性疾病如肥胖症和糖尿病有关。在疾病谱的末端,非酒精性脂肪性肝炎 (NASH) 可能进展为肝硬化和肝细胞癌 (HCC),这对现代社会构成了严重的健康问题。最近,越来越多的源自这种进展性疾病谱的 HCC 病例被识别出来,其严重程度和并发症程度不同。通过更加关注这一新兴病因,并强调其一些独特特征,对当前指南进行更新是必要的。由于疾病的驱动因素复杂且多因素,为了改善未来的结果,更好地了解 NASH 进展为 HCC 可能会有所帮助。促进疾病进展的风险因素以及目前用于监测和治疗与 NASH 相关 HCC 的管理策略构成了本综述的主要内容。

相似文献

1
Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.非酒精性脂肪性肝炎与肝细胞癌风险。
Chin Med J (Engl). 2021 Dec 1;134(24):2911-2921. doi: 10.1097/CM9.0000000000001888.
9
Nonalcoholic fatty liver disease and hepatocellular carcinoma.非酒精性脂肪性肝病与肝细胞癌
Metabolism. 2016 Aug;65(8):1151-60. doi: 10.1016/j.metabol.2016.01.010. Epub 2016 Jan 23.
10
From NASH to HCC: current concepts and future challenges.从 NASH 到 HCC:当前概念和未来挑战。
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7.

引用本文的文献

本文引用的文献

5
Non-invasive fibrosis assessment in non-alcoholic fatty liver disease.非酒精性脂肪性肝病的无创纤维化评估
Chin Med J (Engl). 2020 Nov 20;133(22):2743-2745. doi: 10.1097/CM9.0000000000000989.
8
Hepatocellular carcinoma, novel therapies on the horizon.肝细胞癌,新疗法即将面世。
Chin Clin Oncol. 2021 Feb;10(1):12. doi: 10.21037/cco-20-113. Epub 2020 Jun 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验